This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
—As president of Spectra Pharmaceutical Services Inc, I appreciate the opportunity to respond to Dr Caccamise's letter.Spectra was founded in 1985 on the credo that it would be dedicated to the development of innovative products for the ophthalmic patient and practitioner.Since our inception, we have been true to this credo. We have focused our attention on external surface ocular pathologic conditions, most notably blepharitis. The introduction of I-Scrub in early 1987 represented a scientific approach to the hygienic management of those anatomic structures associated with blepharitis. Since introduction of I-Scrub, approximately 100 ophthalmologists have personally called us to report on its excellent results and favorable patient compliance.Worldwide recognized experts in the area of external ocular disease, namely Drs Leibowitz, Capino, Polack, and Goodman, have independently evaluated I-Scrub and published their clinical impressions as letters in the Archives.Clinical impressions of leading clinicians in all medical
Hannan JA. Interest in the Report of a New Treatment-Reply. Arch Ophthalmol. 1989;107(1):17. doi:10.1001/archopht.1989.01070010018009